Author:
Yu Jingyou,Collier Ai-ris Y.,Rowe Marjorie,Mardas Fatima,Ventura John D.,Wan Huahua,Miller Jessica,Powers Olivia,Chung Benjamin,Siamatu Mazuba,Hachmann Nicole P.,Surve Nehalee,Nampanya Felix,Chandrashekar Abishek,Barouch Dan H.
Abstract
ABSTRACTThe SARS-CoV-2 Omicron variant (B.1.1.529) has three major lineages BA.1, BA.2, and BA.31. BA.1 rapidly became dominant and has demonstrated substantial escape from neutralizing antibodies (NAbs) induced by vaccination2-4. BA.2 has recently increased in frequency in multiple regions of the world, suggesting that BA.2 has a selective advantage over BA.1. BA.1 and BA.2 share multiple common mutations, but both also have unique mutations1 (Fig. 1A). The ability of BA.2 to evade NAbs induced by vaccination or infection has not yet been reported. We evaluated WA1/2020, Omicron BA.1, and BA.2 NAbs in 24 individuals who were vaccinated and boosted with the mRNA BNT162b2 vaccine5 and in 8 individuals who were infected with SARS-CoV-2 (Table S1).
Publisher
Cold Spring Harbor Laboratory
Reference5 articles.
1. Viana R , Moyo S , Amoako DG , et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature 2022.
2. Cele S , Jackson L , Khoury DS , et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 2021.
3. Schmidt F , Muecksch F , Weisblum Y , et al. Plasma Neutralization of the SARS-CoV-2 Omicron Variant. N Engl J Med 2021.
4. Liu L , Iketani S , Guo Y , et al. Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2. Nature 2021.
5. Polack FP , Thomas SJ , Kitchin N , et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020.
Cited by
42 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献